| Literature DB >> 23272097 |
Marcia R Weaver1, Ian Crozier, Simon Eleku, Gyaviira Makanga, Lydia Mpanga Sebuyira, Janepher Nyakake, MaryLou Thompson, Kelly Willis.
Abstract
TRIALEntities:
Mesh:
Year: 2012 PMID: 23272097 PMCID: PMC3522731 DOI: 10.1371/journal.pone.0051319
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Inclusion and exclusion criteria for health facilities and mid-level practitioners.
Figure 2Flow diagram of mid-level practitioners who attended the Integrated Management of Infectious Diseases course.
The figure shows the selection and random allocation of health facilities to two arms. Participants in arm A attended the Integrated Management of Infectious Disease (IMID) training program and On-Site Support. Participants in arm B attended IMID.
Scenario Content Description; Evolution of Scores on New Scenarios by Scenario and Block.
| Patient subgroup | Presenting complaint(s) | Disease entities | Mean score, t0 (%correct) | Mean score, t1 (% correct) | Mean score, t2 (% correct) | |
|
|
|
|
| |||
| 1 | Non-pregnant adult | Cough, fever, vomiting, abdominal pain | TB (smear positive), adverse drug reaction (severe) | 59.1 | 66.3 | 65.9 |
| 2 | Non-pregnant adult | Sore throat, dysphagia, fever, chest pain | AIDS, esophageal candidiasis,TB (suspected extrapulmonary) | 32.8 | 46.0 | 43.8 |
| 4 | Infant | Coma, fever, vomiting, perinatal HIV exposure | Bacterial meningitis, HIV exposure, PMTCT | 34.9 | 39.8 | 46.6 |
| 12 | Child | Cough, fever, diarrhea, wasting | Pneumonia, adverse drug reaction (minor), PMTCT | 33.8 | 50.0 | 48.0 |
|
|
|
|
| |||
| 5 | Child | Fever, respiratory distress, wasting | Malaria (severe), pneumonia, severe acute malnutrition, anemia | 38.2 | 49.6 | 50.3 |
| 6 | Pregnant woman | Fatigue, post-partum fever | Malaria (uncomplicated), post-partum endometritis, anemia | 55.1 | 61.0 | 64.0 |
| 9 | Infant | Clinical worsening on ART | AIDS treatment failure, suspected HIV encephalopathy | 31.4 | 34.5 | 38.1 |
| 11 | Non-pregnant adult | Diarrhea (recurrent), weight loss | Diarrhea (cholera), HIV/AIDS (wasting syndrome) | 41.3 | 50.0 | 50.1 |
|
|
|
|
| |||
| 3 | Non-pregnant adult | Fever, convulsions | Malaria (severe), HIV infection | 34.0 | 46.9 | 43.3 |
| 7 | Infant | Diarrhea, lethargy | Neonatal sepsis | 37.1 | 47.9 | 46.0 |
| 8 | Non-pregnant adult | Adenopathy,clinical worsening on ART | TB-IRIS, adverse drug reaction (severe) | 36.5 | 51.5 | 55.6 |
| 10 | Pregnant woman | Cough, fever | AIDS, smear negative pulmonary TB | 37.5 | 45.9 | 43.4 |
Abbreviations. AIDS: acquired immune deficiency syndrome; ART: antiretroviral therapy; HIV: human immunodeficiency virus; IRIS: immune reconstitution inflammatory syndrome; PMCT: prevention of mother to child transmission (of HIV); TB: tuberculosis.
Although they did not focus on pregnancy, these scenarios also addressed antenatal and post-partum PMTCT protocols.
Figure 3Allocation of case scenarios across testing points.
The 72 IDCAP participants (36 from arm A, 36 from arm B) were randomly assigned to three groups, which contained 12 participants from each arm. The 12 clinical case scenarios were distributed across three, 4-scenario blocks (A, B, and C), and each group was assigned to a different sequence of blocks.
Aggregate Mean New Scenario Scores and Score Changes by Arm and Time.
| Percentage of Points Correct | Absolute Change in Percentage of Points Correct | |||||
| (95% CI) | (95% CI), p-value | |||||
| t0 | t1 | t2 | t0–t1 | t1–t2 | t0–t2 | |
| OSS arm | 37.4 | 49.5 | 49.0 | +12.1 | −0.6 | +11.5 |
| (34.3,40.6) | (46.4,52.7) | (45.8,52.2) | (9.6,14.6), p<0.001 | (−3.1,1.9), p = 0.647 | (9.0,14.1), p<0.001 | |
| Control arm | 41.2 | 48.7 | 50.2 | +7.5 | +1.6 | +9.1 |
| (38.0,44.4) | (45.5,51.8) | (47.0,53.4) | (5.0,10.0), p<0.001 | (−1.0,4.1), p = 0.225 | (6.5,11.6), p<0.001 | |
| Both arms | 39.3 | 49.1 | 49.6 | +9.8 | +0.5 | +10.3 |
| combined | (37.1,41.5) | (46.9,51.3) | (47.4,51.9) | (8.0,11.6), p<0.001 | (−1.3,2.3), p = 0.594 | (8.5,12.1), p<0.001 |
Abbreviations. t0: Pretest (baseline); t1: End of 3-week core course; t2: End of 2nd boost course (24 weeks after t1).